Observational studyNeurosurgical review2026
Analysis of symptomatic brain aneurysms with three-dimensional aneurysm wall enhancement.
Observational study in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiomics model for risk stratification of intracranial aneurysm: a high-resolution vessel wall imaging-based study.BMC medical imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
objectiveTo determine whether three-dimensional quantitative assessment of aneurysm wall enhancement (AWE) improves the identification of high-risk intracranial aneurysms (IAs) compared to existing risk scoring systems. This cross-sectional, multicenter observational study included patients with saccular IAs who prospectively underwent 3T high-resolution MRI between 2018 and 2023 at the University of Iowa, Changhai Hospital, and Ren Ji Hospital. IAs were classified as symptomatic if associated with rupture, sentinel headache, cranial nerve palsy, or neurological symptoms due to mass effect. AWE was quantified using three-dimensional aneurysm wall mapping. The diagnostic performance of the PHASES score was compared to a multivariate logistic regression model developed using all-subsets regression, incorporating PHASES components along with sex, smoking status, aneurysm morphology, and AWE data. A total of 334 patients with 387 saccular IAs were analyzed; 73 aneurysms (19%) were symptomatic. In multivariate analysis, three-dimensional circumferential AWE (3D-CAWE) was independently associated with symptomatic presentation (OR 6.1, 95% CI 2.1–19.5; p < 0.001). The PHASES score achieved an area under the curve (AUC) of 0.64 (95% CI 0.56–0.71) for discriminating symptomatic IAs. A comprehensive model including age, smoking status, size ratio, and 3D-CAWE significantly outperformed PHASES, achieving an AUC of 0.80 (95% CI 0.74–0.85; ΔAUC = 0.16, 95% CI 0.09–0.23; p < 0.001). A comprehensive risk model that integrates clinical variables, aneurysm morphological features, and 3D-CAWE significantly improves the classification of symptomatic IAs compared to the PHASES score alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.